Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Clinical trial NCT06430866 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06430866
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Start date: 2024-09-12
Primary completion: 2026-12-14
Enrollment: 163

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.